Illumina (NASDAQ:ILMN) and QIAGEN N.V. (NYSE:QGEN) have entered into a 15-year agreement aimed at developing and commercializing next-gen sequencing-based in vitro diagnostic (IVD) test kits.
Under the terms of the partnership, QGEN will have
non-exclusive rights to develop and commercialize IVD kits that can be
used with ILMN’s MiSeq Dx and NextSeq 550Dx Systems, including the
rights to expand the deal into future ILMN diagnostic systems.
The parties will also commercialize a lineup of
clinically validated workflows that combine QGEN’s proprietary content
and bioinformatics solutions.
Financial terms are not disclosed.
https://seekingalpha.com/news/3504316-illumina-qiagen-ink-long-term-ivd-diagnostics-partnership
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.